EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 Dezembro 2023 - 9:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to help improve the
lives of patients with retinal diseases, today announced that the
Company granted non-statutory stock options to new employees as
inducement awards outside the Company’s 2023 Long-Term Incentive
Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up
to an aggregate of 13,000 shares of EyePoint Pharmaceuticals common
stock to two new employees. The stock options were granted on
December 15, 2023. The grants were approved by the Compensation
Committee and made as an inducement material to each employee
entering into employment with EyePoint Pharmaceuticals in
accordance with NASDAQ Listing Rule 5635(c)(4). The option awards
have an exercise price of $19.55 per share, the closing price of
EyePoint Pharmaceuticals’ common stock on December 15, 2023. The
options have a ten-year term and vest over four years, with 25% of
the original number of shares vesting on the first anniversary of
the applicable employee’s date of grant and the remainder vesting
in equal monthly installments over the following three years.
Vesting of the options is subject to the employee’s continued
service with EyePoint Pharmaceuticals through the applicable
vesting dates.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage company committed to developing and commercializing
therapeutics to help improve the lives of patients with serious
retinal diseases. The Company's pipeline leverages its proprietary
bioerodible Durasert E™ technology for sustained intraocular drug
delivery. The company’s lead product candidate, EYP-1901, is an
investigational sustained delivery treatment for VEGF-mediated
retinal diseases combining vorolanib, a selective and
patent-protected tyrosine kinase inhibitor (TKI) with Durasert E™.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences
for the localized treatment of all ophthalmic diseases. Additional
pipeline programs include EYP-2301, a promising Tie-2 activator,
razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to
potentially improve outcomes in wet AMD and diabetic eye disease.
The proven Durasert® drug delivery platform has been safely
administered to thousands of patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
For EyePoint
Pharmaceuticals:
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media Contact:Amy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024